These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37419638)

  • 21. Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance.
    Maude RJ; Socheat D; Nguon C; Saroth P; Dara P; Li G; Song J; Yeung S; Dondorp AM; Day NP; White NJ; White LJ
    PLoS One; 2012; 7(5):e37166. PubMed ID: 22662135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial.
    Ouédraogo AL; Bastiaens GJ; Tiono AB; Guelbéogo WM; Kobylinski KC; Ouédraogo A; Barry A; Bougouma EC; Nebie I; Ouattara MS; Lanke KH; Fleckenstein L; Sauerwein RW; Slater HC; Churcher TS; Sirima SB; Drakeley C; Bousema T
    Clin Infect Dis; 2015 Feb; 60(3):357-65. PubMed ID: 25414262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of Ivermectin and Its Metabolites against Asexual Blood Stage Plasmodium falciparum and Its Interactions with Antimalarial Drugs.
    Yipsirimetee A; Tipthara P; Hanboonkunupakarn B; Tripura R; Lek D; Kümpornsin K; Lee MCS; Sattabongkot J; Dondorp AM; White NJ; Kobylinski KC; Tarning J; Chotivanich K
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0173022. PubMed ID: 37338381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study protocol for a cluster randomised controlled factorial design trial to assess the effectiveness and feasibility of reactive focal mass drug administration and vector control to reduce malaria transmission in the low endemic setting of Namibia.
    Medzihradsky OF; Kleinschmidt I; Mumbengegwi D; Roberts KW; McCreesh P; Dufour MK; Uusiku P; Katokele S; Bennett A; Smith J; Sturrock H; Prach LM; Ntuku H; Tambo M; Didier B; Greenhouse B; Gani Z; Aerts A; Gosling R; Hsiang MS
    BMJ Open; 2018 Jan; 8(1):e019294. PubMed ID: 29374672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
    West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)
    Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting-high coverage and safety, but no significant impact on transmission.
    Morris U; Msellem MI; Mkali H; Islam A; Aydin-Schmidt B; Jovel I; Shija SJ; Khamis M; Ali SM; Hodzic L; Magnusson E; Poirot E; Bennett A; Sachs MC; Tarning J; Mårtensson A; Ali AS; Björkman A
    BMC Med; 2018 Dec; 16(1):215. PubMed ID: 30526588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adherence to Mass Drug Administration with Dihydroartemisinin-Piperaquine and
    Finn TP; Porter TR; Moonga H; Silumbe K; Daniels RF; Volkman SK; Yukich JO; Keating J; Bennett A; Steketee RW; Miller JM; Eisele TP
    Am J Trop Med Hyg; 2020 Aug; 103(2_Suppl):37-45. PubMed ID: 32618267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primaquine for reducing Plasmodium falciparum transmission.
    Graves PM; Gelband H; Garner P
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008152. PubMed ID: 22972117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials.
    Phommasone K; van Leth F; Peto TJ; Landier J; Nguyen TN; Tripura R; Pongvongsa T; Lwin KM; Kajeechiwa L; Thwin MM; Parker DM; Wiladphaingern J; Nosten S; Proux S; Nguon C; Davoeung C; Rekol H; Adhikari B; Promnarate C; Chotivanich K; Hanboonkunupakarn B; Jittmala P; Cheah PY; Dhorda M; Imwong M; Mukaka M; Peerawaranun P; Pukrittayakamee S; Newton PN; Thwaites GE; Day NPJ; Mayxay M; Hien TT; Nosten FH; Cobelens F; Dondorp AM; White NJ; von Seidlein L
    PLoS One; 2020; 15(2):e0228190. PubMed ID: 32023293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term Impact of Mass Drug Administration With Dihydroartemisinin Plus Piperaquine on Malaria in Southern Province Zambia: A Cluster-Randomized Controlled Trial.
    Eisele TP; Bennett A; Silumbe K; Finn TP; Chalwe V; Kamuliwo M; Hamainza B; Moonga H; Kooma E; Chizema Kawesha E; Yukich J; Keating J; Porter T; Conner RO; Earle D; Steketee RW; Miller JM
    J Infect Dis; 2016 Dec; 214(12):1831-1839. PubMed ID: 27923947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial.
    Eisele TP; Silumbe K; Finn T; Chalwe V; Kamuliwo M; Hamainza B; Moonga H; Bennett A; Yukich J; Keating J; Steketee RW; Miller JM
    Trials; 2015 Aug; 16():347. PubMed ID: 26268804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border.
    Saito M; Carrara VI; Gilder ME; Min AM; Tun NW; Pimanpanarak M; Viladpai-Nguen J; Paw MK; Haohankhunnatham W; Konghahong K; Phyo AP; Chu C; Turner C; Lee SJ; Duanguppama J; Imwong M; Bancone G; Proux S; Singhasivanon P; White NJ; Nosten F; McGready R
    BMC Med; 2021 Jun; 19(1):132. PubMed ID: 34107963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Epidemiology of Plasmodium falciparum Malaria in the Bijagos Islands of Guinea-Bissau.
    McGregor D; Texeira da Silva E; Grignard L; Goncalves A; Vasileva H; Mabey D; Last A
    Am J Trop Med Hyg; 2021 Mar; 104(6):2117-2122. PubMed ID: 33782209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study.
    Amaratunga C; Lim P; Suon S; Sreng S; Mao S; Sopha C; Sam B; Dek D; Try V; Amato R; Blessborn D; Song L; Tullo GS; Fay MP; Anderson JM; Tarning J; Fairhurst RM
    Lancet Infect Dis; 2016 Mar; 16(3):357-65. PubMed ID: 26774243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria.
    Isba R; Zani B; Gathu M; Sinclair D
    Cochrane Database Syst Rev; 2015 Feb; 2015(2):CD011547. PubMed ID: 25702785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission.
    Graves PM; Choi L; Gelband H; Garner P
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD008152. PubMed ID: 29393511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial.
    Makenga G; Baraka V; Francis F; Nakato S; Gesase S; Mtove G; Madebe R; Kyaruzi E; Minja DTR; Lusingu JPA; Geertruyden JV
    Lancet Glob Health; 2023 Aug; 11(8):e1277-e1289. PubMed ID: 37474234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial.
    Hsiang MS; Ntuku H; Roberts KW; Dufour MK; Whittemore B; Tambo M; McCreesh P; Medzihradsky OF; Prach LM; Siloka G; Siame N; Gueye CS; Schrubbe L; Wu L; Scott V; Tessema S; Greenhouse B; Erlank E; Koekemoer LL; Sturrock HJW; Mwilima A; Katokele S; Uusiku P; Bennett A; Smith JL; Kleinschmidt I; Mumbengegwi D; Gosling R
    Lancet; 2020 Apr; 395(10233):1361-1373. PubMed ID: 32334702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of
    Chishimba S; Mwenda M; Mambwe B; Mulube C; Chalwe V; Moonga H; Hamainza B; Chizema-Kawesha E; Steketee RW; Domingo G; Fraser M; Kahn M; Pal S; Silumbe K; Conner RO; Bennett A; Porter TR; Eisele TP; Miller JM; Bridges DJ
    Am J Trop Med Hyg; 2020 Aug; 103(2_Suppl):82-89. PubMed ID: 32618252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ivermectin for causal malaria prophylaxis: a randomised controlled human infection trial.
    Metzger WG; Theurer A; Pfleiderer A; Molnar Z; Maihöfer-Braatting D; Bissinger AL; Sulyok Z; Köhler C; Egger-Adam D; Lalremruata A; Esen M; Lee Sim K; Hoffman S; Rabinovich R; Chaccour C; Alonso P; Mordmüller BG; Kremsner PG
    Trop Med Int Health; 2020 Mar; 25(3):380-386. PubMed ID: 31808594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.